You just read:

Janssen Announces Submission of New Drug Application to U.S. FDA For the First Monthly, Injectable, Two-Drug Regimen of Rilpivirine and Cabotegravir for Treatment of HIV

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Apr 29, 2019, 07:23 ET